DNA-aptamer targeting vimentin for tumor therapy in vivo

Nucleic Acid Therapeutics

Volumn 24, Issue 2, 2014, Pages 160-170

  Zamay, Tatyana N ^a   Kolovskaya, Olga S ^a   Glazyrin, Yury E ^a   Zamay, Galina S ^a   Kuznetsova, Svetlana A ^b   Spivak, Ekaterina A ^a   Wehbe, Mohamed ^c   Savitskaya, Anna G ^a   Zubkova, Olga A ^a   Kadkina, Anastasia ^a   Wang, Xiaoyan ^c   Muharemagic, Darija ^c   Dubynina, Anna ^a   Sheina, Yuliya ^d   Salmina, Alla B ^a   Berezovski, Maxim V ^c   Zamay, Anna S ^a,b  

^a KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF CHEMISTRY AND CHEMICAL TECHNOLOGY   (Russian Federation)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Center for Reproductive Medicine   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; ARABINOGALACTAN; ENHANCED GREEN FLUORESCENT PROTEIN; NAS 24; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL NUCLEUS; CELL ORGANELLE; CONTROLLED STUDY; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; FLOW CYTOMETRY; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APTAMERS, NUCLEOTIDE; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; DRUG CARRIERS; GALACTANS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEPATOCYTES; HUMANS; LARIX; LIVER; MALE; MICE; MICE, INBRED ICR; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; VIMENTIN;

EID: 84896993887     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0471     Document Type: Article

References (49)

1. AHMED, M., and NARAIN, R. (2012). Intracellular delivery of DNA and enzyme in active form using degradable carbohydrate-based nanogels. Mol. Pharm. 9, 3160-3170. DOI: 10. 1021/mp300255p.
2. AL-HENDY, A., and SALAMA, S. (2006). Gene therapy and uterine leiomyoma: a review. Hum. Reprod. Update 12, 385-400.
3. BEREZOVSKI, M. V., LECHMANN, M., MUSHEEV, M. U., MAK, T. W., and KRYLOV, S. N. (2008). Aptamer-facilitated biomarker discovery (AptaBiD). J. Am. Chem. Soc. 130, 9137-9143.
4. BYUN, Y., CHEN, F., CHANG, R., TRIVEDI, M., GREEN, K. J., CRYNS, V. L. (2001). Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ. 8, 443-450.
5. CAWLEY, D. B., SIMPSON, D. L., and HERSCHMAN, H. R. (1981). Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes. Proc. Nat. Acad. Sci. U. S. A. 78, 3383-3387.
6. CHALLA, A. A., and STEFANOVIC, B. (2011). A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol. Cell Biol. 31, 3773-3789.
7. CHOI, K., KIM, K., KWON, I. C., KIM, I. S., and AHN H. J. (2012). Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. Mol. Pharm. DOI: 10. 1021/mp300211a.
8. CODREA V., HAYNER M, HALL B., JHAVERI S., and ELLINGTON A. (2010). In vitro selection of RNA aptamers to a small molecule target. Curr. Prot. Nucleic Acid Chem. DOI:10. 1002/0471142700. nc0905s40.
9. COX, J., and MANN, M. (2008). MaxQuant enables high peptide identification rates, individualized p. p. b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372.
10. ELIYAHU H., BARENHOLZ Y., and DOMB A. J. (2005). Polymers for DNA delivery. Molecules 10, 34-64.
11. ELLINGTON, A., and SZOSTAK, J. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
12. FUYUHIRO, Y., YASHIRO, M., NODA, S., KASHIWAGI, S., MATSUOKA, J., DOI, Y., KATO, Y., KUBO, N., OHIRA, M., and HIRAKAWA, K. (2010). Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 30, 239-243.
13. GABOR, F. BOGNER, E. WEISSENBOECK, A., and WIRTH, M. (2004). The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev. 56, 459-480.
14. GILLES, C., POLETTE, M., MESTDAGT, M., NAWROCKIRABY, B., RUGGERI, P., BIREMBAUT, P., and FOIDART, J. M. (2003). Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 63, 2658-2664.
15. GROMAN, E. V., ENRIQUEZ, P. M., JUNG C., and JOSEPHSON, L. (1994). Arabinogalactan for hepatic drug delivery. Bioconjug. Chem. 5, 547-556.
16. HU, L., LAU, S. H., TZANG, C. H., WEN, J. M., WANG, W., XIE, D., HUANG, M., WANG, Y., WU, M. C., HUANG, J. F., et al. (2004). Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23, 298-302.
17. HUANG Y. F., SHANGGUAN D., LIU H., PHILLIPS J. A., ZHANG X., CHEN Y., and TAN W. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10, 862-868.
18. IVASKA, J., PALLARI, H. M., NEVO, J., and ERIKSSON, J. E. (2007). Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 313, 2050-2062.
19. JIAN, Y, GAO, Z, SUN, J, SHEN FENG QF, JING Y, YANG C. (2009). RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene 28, 4201-4211.
20. JIN, H., MOROHASHI, S., SATO, F., et al. (2010). Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. Biomed. Res. 31, 105-112.
21. JULIANO, R., ALAM, M. R., DIXIT, V., KANG, H. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 4158-4171.
22. KAZUKI, Y., HOSHIYA, H., TAKIGUCHI, M., ABE, S., IIDA, Y., OSAKI, M., KATOH, M., HIRATSUKA, M., SHIRAYOSHI, Y., HIRAMATSU, K., et al. (2011). Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther. 18, 384-393.
23. KEEFE, A. D., PAI S., and ELLINGTON A. (2010). Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550.
24. KOLOVSKAYA, O. S., SAVITSKAYA, A. G., ZAMAY, T. N., RESHETNEVA, I. T., ZAMAY, G. S. et al. (2013). Development of bacteriostatic DNA aptamers for salmonella. J. Med. Chem. 56, 1564-1572.
25. KORSCHING, E., PACKEISEN, J., LIEDTKE, C., HUNGERMANN, D., WULFING, P., VAN DIEST, P. J., BRANDT, B., BOECKER, W., and BUERGER, H. (2005). The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential. J. Pathol. 206, 451-457.
26. LABIB, M., ZAMAY, A. S., MUHAREMAGIC, D., CHECHIK A., BELL, J. C., and BEREZOVSKI, M. V. (2012). Electrochemical differentiation of epitope-specific aptamers. Anal. Chem. 84, 2548-2556.
27. LAHAT, G., ZHU, Q. S., HUANG, K. L., WANG, S., BOLSHAKOVA, S., LIU, J., TORRES, K., LANGLEY, R. R., LAZAR, A. J., HUNG, M. C. and LEV, D. (2010). Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5, e10105.
28. DOI:10. 1371/journal. pone. 001010.
29. LEHR, C. M., and GABOR, F. (2004). Lectins and glycoconjugates in drug delivery and targeting. Adv. Drug Deliv. Rev. 56, 419-420.
30. LI, H., SUN X. ZHAO, D., and ZHANG, Z. (2012). A cellspecific poly(ethylene glycol) derivative with a wheat-like structure for efficient gene delivery. Mol. Pharm. 9, 2974-2985. DOI: 10. 1021/mp300321n.
31. LI, M., ZHANG, B., SUN, B., WANG, X., BAN, X., SUN, T., LIU, Z., and ZHAO, X. (2010). A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J. Exp. Clin. Cancer Res. 29, 109.
32. LI, N., NGUYEN H. H., BYROM, M., and ELLINGTON, A. D. (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 6, e20299, 1-10.
33. LI, Y., HUANG, G., DIAKUR, J., and WIEBE, L. I. (2008). Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr. Drug Deliv. 5, 299-302.
34. MEYER C., HAHN U., and RENTMEISTER A. (2011). Cellspecific aptamers as emerging therapeutics. J. Nucleic Acids 2011, 904750. DOI:10. 4061/2011/904750.
35. MUHAREMAGIC, D., LABIB, M., GHOBADLOO, S. M., ZAMAY, A. S., BELL, J. C., and BEREZOVSKI, M. V. (2012). Anti-fab aptamers for shielding virus from neutralizing antibodies. J. Am. Chem. Soc. 134, 17168-17177.
36. RAY P., and WHITE R. R. (2010). Aptamers for targeted drug delivery. Pharmaceuticals 3, 1761-1778.
37. RHO, J. H., ROEHRL, M. H., and WANG, J. Y. (2009). Glycoproteomic analysis of human lung adenocarcinomas using glycoarrays and tandem mass spectrometry: differential expression and glycosylation patterns of vimentin and fetuin A isoforms. Protein J. 28, 148-160.
38. SATELLI, A, LI, S. (2011). Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol. Life Sci. 68, 3033-3046.
39. SELLINS, K., FRADKIN, L., LIGGITT, D., and DOW, S. (2005). Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol. Ther. 12, 451-459.
40. SETHI, S., MACOSKA, J., CHEN, W., and SARKAR, F. H. (2010). Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 3, 90-99.
41. STRIBLEY, J. M., REHMAN, K. S., NIU, H., and CHRISTMAN, G. M. (2002). Gene therapy and reproductive medicine. Fertil. Steril. 77, 645-657.
42. SUDA, T., SUDA, K., and LIU, D. (2008). Computer-assisted hydrodynamic gene delivery. Mol. Ther. 16, 1098-1104.
43. TUERK, C., and GOLD, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
44. ULRICH, H. (2006). RNA aptamers: from basic science towards therapy. Handb. Exp. Pharmacol. 173, 305-326.
45. VALLADEAU, J., DUVERT-FRANCES, V, PIN, J. J., KLEIJMEER, M. J., AIT-YAHIA, S., RAVEL, O., VINCENT, C., VEGA, F., HELMS, A., GORMAN, D., et al. (2001). Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J. Immunol. 167, 5767-5774.
46. VORA, H. H., PATEL, N. A., RAJVIK, K. N., MEHTA, S. V., BRAHMBHATT, B. V., SHAH, M. J., SHUKLA, S. N., and SHAH, P. M. (2009). Cytokeratin and vimentin expression in breast cancer. Int. J. Biol. Markers. 24, 38-46.
47. WHITEHEAD, K. A., LANGER, R., and ANDERSON, D. G. (2009). Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138.
48. WILLIAMS, A. A., HIGGINS, J. P., ZHAO, H., LJUNBERG, B., and BROOKS, J. D. (2009). CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin. Pathol. 9, 9.
49. ZHAO, Y., YAN, Q., LONG, X., CHEN, X., and WANG, Y. (2008). Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem. Funct. 26, 571-577.